Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160544 | 0.81 | CYP2C9 (0.35) | TP53CYP2C9CYP2C19NPSR1MAPT | |
| SCHEMBL31157616 | 0.81 | CHRNA4 (0.40) | TP53CYP2C9CYP2C19NPSR1MAPT | |
| SCHEMBL17781246 | 0.70 | ALDH1A1 (0.35) | TP53LMNAMAPTCA12CA1 | |
| SCHEMBL8957191 | 0.70 | MAPK1 (0.42) | LMNACYP2C9CYP2C19NPSR1MAPT | |
| SCHEMBL5410677 | 0.69 | GRM6 (0.35) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL828580 | 0.68 | EGFR (0.41) | TP53CYP2C9CYP2C19NPSR1MAPT | |
| SCHEMBL1292847 | 0.68 | NAPRT (0.56) | HSD17B10GRM6KDM4EALDH1A1HPGD | |
| SCHEMBL6261311 | 0.68 | ATR (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1585342 | 0.68 | GAA (0.37) | SMN1; SMN2MAPTCA12CA1CA2 | |
| SCHEMBL29923922 | 0.68 | NAPRT (0.56) | HSD17B10GRM6KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372598-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | LegoChem Biosciences, Inc. (KR) | 2018-09-12 | — | — | EP | disclosed |
| EP-2331529-B1 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCES INC (KR) | 2014-11-05 | — | — | EP | disclosed |
| US-8846669-B2 | Oxazolidinone derivative and medical composition containing same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| EP-2692727-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LegoChem Biosciences, Inc. (KR) | 2014-02-05 | — | — | EP | disclosed |
| US-8242113-B2 | Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-08-14 | — | — | US | disclosed |
| US-20110178293-A1 | Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-07-21 | — | — | US | disclosed |
| EP-2331529-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | Legochem Bioschences Ltd. (KR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036000-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178293-A1 | Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof | PAM, PYCARD, PEPD | TP53 3132/4885SMN1; SMN2 4143/4885NPC1 4086/4885 |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | TP53 3783/4885SMN1; SMN2 4157/4885NPC1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.